北京市中伦律师事务所 北京市中伦律师事务所 关于甘李药业股份有限公司 2022 年及 2024 年限制性股票激励计划 相关调整事项的法律意见书 二〇二五年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 关于甘李药业股份有限公司 2022 年及 2024 年限制性股票激励计划相关调整事项的 法律意见书 致：甘李药业股份有限公司 根据甘李药业股份有限公司（以下简称"甘李药业"、"公司"）与北京市 中伦律师事务所（以下简称"本所"）签订的《法律服务合同》的约定及受本所 指派，本所律师作为公司 2022 ...

甘李药业股份有限公司 二〇二四年度 内部控制审计报告 致同会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询" 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.or）"进行查询 "" " 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 致同审字（2025）第 110A014775 号 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 Grant Thornton 致同 四、财务报告内部控制审计意见 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了甘李药业股份有限公司（以下简称甘李药业公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 ...

致同会计师事务所 (特殊普通合伙) 甘李药业股份有限公司 2024 年度募集资金存放与实际使用情况 鉴证报告 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查询 " 2024 2024 1-9 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 2024 致同专字（2025）第 110A009023 号 我们接受委托，对后附的甘李药业股份有限公司（以下简称 甘李药业） 《2024 年度募集资金存放与实际使用情况的专项报告》（以下简称"专项报 告"）执行了合理保证的鉴证业务。 按照《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求（2022 年修订）》和《上海证券交易所上市公司自律监管指引第 1 号—— 规范运作》的要求编制 2024 年度专项报告，保证其内容真实、准确、完整，不 存 ...

甘李药业股份有限公司 二〇二四年度 审计报告 致同会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn）"进行查测 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http:///ac.mof.gov.cn）"进行查测 " | 1-5 | | --- | | 1-2 | | 3 | | 4 | | 5-8 | | 9-85 | 中国北京朝阳区建国门外大街 22 号 赛特广场 5 层邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 致同审字（2025）第 110A014773 号 我们审计了甘李药业股份有限公司（以下简称甘李药业）财务报表，包 括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润 表、合并及公司现金流量表、合并及公司股东权益变动表以及相关财务报表 附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编 制，公允反映了甘李药业 2024 年 12 月 31 日的合并及公 ...

关于甘李药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：甘李药业股份有限公司 审计单位：致同会计师事务所(特殊普通合伙) 联系电话：+86 10 8566 5588 甘李药业股份有限公司 控股股东及其他关联方资金占用情况的专项说明 （截止 2024 年 12 月 31 日） 目 录 页 次 一、 控股股东及其他关联方资金占用情况的专项说 明 1-2 二、 甘李药业股份有限公司 2024 年度非经营性资 金占用及其他关联资金往来情况汇总表 1 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 关于甘李药业股份有限公司 致同专字（2025）第 110A009022 号 甘李药业股份有限公司全体股东： 我们接受甘李药业股份有限公司（以下简称"甘李药业"）委托，根据 中国注册会计师执业准则审计了甘李药业 2024 年 12 月 31 日的合并及公司 资产负债表，2024 年度合并及公司利润表、合并 ...

甘李药业股份有限公司 2024 年度独立董事述职报告 作为甘李药业股份有限公司（以下简称"公司"）的独立董事，2024 年本人能 够严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理 办法》等法律、法规和《公司章程》的规定，恪尽职守，勤勉尽责，充分发挥独立 董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人的工作情况 汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 本人，何艳青，女，1985 年出生，中国国籍，无永久境外居留权，大学本科， 中国注册会计师，毕业于河北经贸大学。2008 年至 2023 年，任职于北京金华诚信 会计师事务所有限责任公司，担任审计助理、项目经理职务；2024 年至今，担任 北京合方会计师事务所（特殊普通合伙）合伙人；2019 年至今，担任公司独立董 事。 （二）是否存在影响独立性的情况说明 作为公司独立董事，任职期间，本人未在公司担任除独立董事以外的其他职务， 与公司、公司的控股股东不存在可能妨碍本人进行独立客观判断的关系，本人也没 有从公司、公司控股股东及其关联方取得额外的、未予披露的其他利益。因此，不 存在影响独立 ...

甘李药业股份有限公司 2024 年度独立董事述职报告 作为甘李药业股份有限公司（以下简称"公司"）的独立董事，2024 年本人能 够严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董事管理 办法》等法律、法规和《公司章程》的规定，恪尽职守，勤勉尽责，充分发挥独立 董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人的工作情况 汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 本人，郑国钧，男，1968 年出生，中国国籍，博士，毕业于中国医学科学院。 1998 年至 2000 年在中国科学院微生物研究所从事博士后研究工作；2000 年至 2001 年在法国科学研究中心从事博士后研究工作；2002 年至今，任北京化工大学 教授；2019 年至今，担任公司独立董事。 （二）是否存在影响独立性的情况说明 作为公司独立董事，任职期间，本人未在公司担任除独立董事以外的其他职务， 与公司、公司的控股股东不存在可能妨碍本人进行独立客观判断的关系，本人也没 有从公司、公司控股股东及其关联方取得额外的、未予披露的其他利益。因此，不 存在影响独立性的情况。 二、2024 年度履 ...

甘李药业股份有限公司 2024 年度独立董事述职报告 作为甘李药业股份有限公司（以下简称"公司"）的独立董事，2024 年本 人能够严格按照《公司法》《证券法》《上市公司治理准则》《上市公司独立董 事管理办法》等法律、法规和《公司章程》的规定，恪尽职守，勤勉尽责，充分 发挥独立董事的独立作用，维护了公司及全体股东的利益。现将 2024 年度本人 的工作情况汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 本人，昌增益，公司独立董事，男，1965 年出生，博士，毕业于美国贝勒 医学院。1996 年至 2003 年在清华大学生物系任教；2003 年调北京大学生命科 学学院工作，现任北京大学生命科学学院教授、博士生导师、北京大学跨院系 蛋白质科学中心主任等职务；2022 年 5 月至今，担任公司独立董事。 （二）是否存在影响独立性的情况说明 作为公司独立董事，任职期间，本人未在公司担任除独立董事以外的其他职 务，与公司、公司的控股股东不存在可能妨碍本人进行独立客观判断的关系，本 人也没有从公司、公司控股股东及其关联方取得额外的、未予披露的其他利益。 因此，不存在影响独立性的情况。 二、202 ...

Financial Performance - The company's revenue for Q1 2025 reached CNY 984.87 million, a 75.76% increase compared to CNY 560.33 million in the same period last year[5]. - Net profit attributable to shareholders was CNY 311.92 million, reflecting a significant increase of 224.90% from CNY 96.00 million year-on-year[5]. - The net profit excluding non-recurring gains and losses was CNY 214.65 million, up 1,150.17% from CNY 17.17 million in the previous year[5]. - Basic earnings per share rose to CNY 0.53, representing a 231.25% increase from CNY 0.16 year-on-year[5]. - Total operating revenue for Q1 2025 reached ¥984.87 million, a significant increase of 75.7% compared to ¥560.33 million in Q1 2024[21]. - Net profit for Q1 2025 was ¥311.92 million, up 225.5% from ¥96.00 million in Q1 2024[21]. - Basic and diluted earnings per share for Q1 2025 were both ¥0.53, compared to ¥0.16 in Q1 2024[22]. - The company reported a total profit of ¥360.39 million for Q1 2025, compared to ¥113.56 million in Q1 2024, reflecting a growth of 217.5%[21]. - The company’s total comprehensive income for Q1 2025 was ¥312.26 million, compared to ¥95.89 million in Q1 2024, marking a growth of 226.5%[21]. Cash Flow and Assets - Cash flow from operating activities was CNY 158.75 million, a 95.29% increase compared to CNY 81.29 million in the same period last year[5]. - Cash flow from operating activities for Q1 2025 was ¥158.75 million, an increase of 95.5% from ¥81.29 million in Q1 2024[23]. - The company's total assets increased by 2.01% to CNY 12.28 billion compared to the end of the previous year[5]. - The company's total assets as of March 31, 2025, amount to ¥12,284,434,818.79, an increase from ¥12,042,916,391.88 at the end of 2024[18][19]. - Current assets total ¥3,900,272,940.75, showing an increase from ¥3,790,858,209.05[18]. - The company's cash and cash equivalents stand at ¥1,058,837,161.68, up from ¥902,777,760.68[18]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥372.30 million, up from ¥337.92 million at the end of Q1 2024[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 74,987[15]. - The largest shareholder, Gan Zhongru, holds 205,643,757 shares, accounting for 34.21% of total shares[15]. - The company has pledged 28,210,000 shares held by Gan Zhongru[15]. - The equity attributable to shareholders of the parent company is ¥11,312,123,449.60, compared to ¥11,054,470,662.18 previously[19]. - The company has no significant changes in shareholder relationships or actions during the reporting period[17]. Sales Performance - Domestic sales revenue was CNY 889 million, up 80.07% from the previous year, driven by significant growth in insulin product sales[12]. - International sales revenue reached CNY 95 million, a 45.21% increase compared to the same period last year, supported by expanding international market efforts[14]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥739.37 million, an increase of 36.4% from ¥541.95 million in Q1 2024[21]. - Research and development expenses for Q1 2025 were ¥130.45 million, slightly down from ¥133.12 million in Q1 2024[21]. Future Plans - The company plans to continue deepening its global layout and drive export business growth through innovation[14]. Inventory and Liabilities - The company reported an increase in inventory to ¥1,113,062,811.37 from ¥1,052,906,832.75[18]. - Total liabilities decreased to ¥972,311,369.19 from ¥988,445,729.70[19].

Financial Performance - In 2023, the company achieved a revenue of CNY 3,045.35 million, representing a year-on-year growth of 16.77%[7] - The net profit attributable to shareholders reached CNY 614.66 million, with a significant year-on-year increase of 80.75%[7] - The company reported a significant focus on innovative drug development, with multiple products in the pipeline[26] - The company achieved a revenue of 3,045.35 million yuan in 2024, representing a year-on-year growth of 16.77%, and a net profit attributable to shareholders of 614.66 million yuan, up 80.75% year-on-year[46] - The net profit attributable to shareholders for 2024 was approximately CNY 614.66 million, a significant increase of 80.75% from CNY 340.07 million in 2023[36] - The company reported a significant increase in R&D investment for the GZR18 injection, totaling RMB 15,112.94 million, with a year-on-year increase of 63.87%[172] - The company achieved an EBITDA of CNY 798 million, which is a 74.92% increase compared to the previous year[132] Market Position and Strategy - The market share in the domestic market rose to the second position in the industry, only behind Novo Nordisk, covering 41,000 medical institutions[7] - The company aims to transition from "China manufacturing" to "global innovation," focusing on high-quality development and patient-centered approaches[4] - The company is actively expanding its international market presence, including establishing a local insulin production facility in Brazil[10] - The company aims to enhance its global brand influence and market share by launching new products like GZR18 and GZR4, which are expected to diversify treatment options for diabetes patients[109] - The company is focusing on expanding its product line by actively seeking external quality targets in addition to self-developed new drugs[189] Research and Development - Research and development investment reached CNY 646 million, accounting for 21.20% of total revenue[9] - The company is advancing its innovative insulin products, with GZR4 and GZR18 entering critical clinical phases, showing promising results in efficacy[9] - The company is developing GZR101, a novel combination insulin product, aimed at diabetes treatment[25] - GZR33, a long-acting insulin analog, is also under development, expected to enhance diabetes management[25] - The company has established a comprehensive R&D management system, ensuring projects meet expected goals through various research phases from target research to clinical trials[118] Clinical Trials and Approvals - The company completed the Phase II clinical study of GZR18 injection, showing superior efficacy in reducing HbA1c and weight compared to Semaglutide after 24 weeks of treatment[48] - GZR4 injection also achieved primary endpoints in Phase II clinical trials, demonstrating better efficacy in lowering HbA1c compared to Degludec after 16 weeks of treatment[48] - The company received FDA preliminary feedback and passed EMA's GMP inspection, marking a significant milestone for its insulin products in the EU market[47] - The company received approval from the China CDE for the III phase clinical study of Bofanglupatide for obesity/overweight in December 2024, with the first subject dosed successfully[56] - The company’s GZR4 injection has also been approved for Phase III clinical research in China, with the first patient dosing completed in February 2025[167] Procurement and Supply Chain - The company secured a procurement agreement for 46.86 million units of insulin, marking a 32.6% increase compared to the previous procurement cycle[7] - The insulin procurement cycle initiated in May 2022 will last for two years, impacting pricing strategies[25] - The new insulin procurement policy announced in March 2024 will extend until December 31, 2027, indicating a long-term strategy[25] - The company successfully participated in the national drug centralized procurement for insulin, resulting in a price adjustment that positively impacted overall revenue by CNY 315 million[140] - The company has established a production partnership in Brazil, marking a significant milestone in local insulin production capabilities[80] Talent and Human Resources - A restricted stock incentive plan was implemented to enhance talent retention and drive long-term development[10] - The company has implemented a comprehensive talent development strategy, focusing on nurturing management personnel across all levels to support international growth[90] - The company has established long-term partnerships with major universities to build a talent pool, enhancing its brand influence in the academic community[91] - The company has received multiple employer brand awards, including Forbes' Top 100 Returnees and Best Employers, which enhances its attractiveness to talent[92] Regulatory Compliance and Risk Management - The board of directors confirmed the authenticity, accuracy, and completeness of the annual report, ensuring no significant omissions or misleading statements[14] - There are no significant risks that could materially affect the company's operations during the reporting period[19] - The company is closely monitoring policies related to grassroots healthcare services and plans to increase R&D investment to improve service quality for diabetes patients in rural areas[100] - The company faces industry policy risks due to increasing regulatory scrutiny and the implementation of various healthcare policies in China[188] Financial Management and Investments - The company has distributed a total cash dividend of CNY 1.613 billion since its IPO in 2020, with a projected dividend of CNY 899 million for 2024, representing 146.31% of the net profit attributable to ordinary shareholders for that year[93] - The company’s financial disclosures are available through Shanghai Securities News and China Securities Journal[31] - The company has engaged Deloitte as its accounting firm, ensuring compliance and oversight[33] - The company is committed to high-quality sustainable development and cost control to maximize enterprise benefits and create continuous value for shareholders[93] International Expansion - The company is actively expanding its international market presence, particularly in emerging markets along the "Belt and Road" initiative[78] - The company received regulatory approval for its insulin products in Malaysia, marking a significant milestone in its international expansion strategy in Southeast Asia[81] - The internationalization strategy is focused on expanding overseas markets to ensure a steady supply of insulin and reduce healthcare costs for diabetes patients globally[187] Product Development and Innovation - The company has a robust pipeline with multiple products in clinical stages, including GZR18 and GZR4, focusing on diabetes and obesity treatment[50] - The company’s innovative approach in developing oral GLP-1RA formulations reflects its commitment to improving patient experience and treatment adherence[59] - The company is focusing on research in various fields, including oncology and cardiovascular diseases, to provide a broader range of treatment options[109] - The company has successfully developed multiple third-generation insulin analogs, positioning itself as a leader in the domestic insulin production industry[110]